Mardi Dier - 01 Mar 2022 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: CFO & Executive Vice President
Signature: /s/ Karah Parschauer, attorney-in-fact
Issuer symbol: RARE
Transactions as of: 01 Mar 2022
Net transactions value: -$62,686
Form type: 4
Filing time: 03 Mar 2022, 17:12:02 UTC
Previous filing: 14 Oct 2021
Next filing: 22 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Sale	$35,575	-534	-1.4%	$66.62	38,228	01 Mar 2022	Direct	F1
transaction	RARE	Common Stock	Award	$0	+14,000	+37%	$0.000000	52,228	01 Mar 2022	Direct	F2
transaction	RARE	Common Stock	Sale	$27,111	-420	-0.8%	$64.55	51,808	03 Mar 2022	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RARE	Stock Option (Right to Buy)	Award	$0	+24,900		$0.000000	24,900	01 Mar 2022	Common Stock	24,900	$67.37	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2	Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
F3	The sales on March 3, 2022 reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F4	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F5	On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.